Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics (Premium)
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zhejiang Hisun Pharmaceutical Co Ltd Announces FY 2012 Net Profit Outlook Below Analysts' Estimate


Tuesday, 22 Jan 2013 07:00pm EST 

Zhejiang Hisun Pharmaceutical Co Ltd announced that it expects its net profit for fiscal year (FY) 2012 to decrease by 35% to 45%, compared to the net profit of FY 2011 (RMB 504,081,307.43). The Company cited the investment in its new subsidiary and the COmpany's research and development, and decreased price of partial products as the main reason for the forecast. According to I/B/E/S Estimates, analysts expect the Company's net profit for fiscal year 2012 to be RMB 451.92 million.